Ann: Positive New HER-Vaxx HERIZON Data Presented at ESMO Asia, page-22

not quite true. The main reason for doing this is time. Getting the right candidates for trial is quite challenging and recruiting more adds time to the whole length of the trial and readout. I think there’s merit, especially for such significant disruptive benefit to patients to do this. If I was on the receiving end of treatment today and had fairly short life expectancy with the options in market for SOC, I’d be quite happy with increased likely OS and fewer side effects with a p value of 0.1.
I think IMU is doing the right and responsible thing here by pushing along as fast as possible within the constraints of the existing regulatory framework and being fully transparent of the results.

cheers,

YS